Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
May 09 2022 - 8:35AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial
biopharmaceutical company working to develop and launch the
first FDA-approved ophthalmic formulation of bevacizumab for
use in retinal indications, today announced that Russ Trenary,
President & Chief Executive Officer of Outlook Therapeutics
will participate in the Virtual Investor CEO Spotlight on
Wednesday, May 11, 2022 at 1:00 PM ET.
For the virtual event, Outlook Therapeutics will
provide a corporate overview and discuss their investigational
therapy, ONS-5010/ LYTENAVA™ (bevacizumab-vikg), which is poised to
potentially be the first FDA-approved ophthalmic formulation of
bevacizumab for use in treating wet AMD. In addition to the
moderated portion of the event, all investors and interested
parties will have the opportunity to submit questions live during
the event. The Company will answer as many questions as possible
during the event.
A live video webcast will be available on the
Events page of the Investors section of Outlook Therapeutics’
website (outlooktherapeutics.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for 90 days.About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a pre-commercial
biopharmaceutical company working to develop and launch ONS-5010/
LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the
first FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD, DME and BRVO. Outlook
Therapeutics has submitted its Biologics License Application (BLA)
to the U.S. Food and Drug Administration (FDA) for ONS-5010 to
treat wet AMD. The submission is supported by Outlook Therapeutics’
wet AMD registration clinical program, which consists of three
clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010
ophthalmic bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases in
the United States, United Kingdom, Europe, Japan and other markets.
For more information, please
visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024